Evidence map›Paper›PMID 33928382›Full record

ReviewJournal of industrial microbiology & biotechnology2021

Mechanisms of action of ribosomally synthesized and posttranslationally modified peptides (RiPPs).

Li Cao, Truc Do, A James Link

Abstract readReview
In one paragraph

Review in Journal of industrial microbiology & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed.

  1. Review
  2. Co-opting the bacterial lipoprotein pathway for the biosynthesis of lipidated macrocyclic peptides.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. The rise and future of peptide-based antimicrobials.Journal of microbiology (Seoul, Korea) · 2026
    Review
  4. Article
  5. A ribosomally synthesized and posttranslationally modified peptide with ADP-ribosylation.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
  7. Review
  8. Genome Sequence and Antimicrobial Production ofmicroPublication biology · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Biosynthesis of Macrocyclic Peptides by Formation and Crosslinking ofbioRxiv : the preprint server for biology · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Li CaoDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ 08544, USA.ORCID 0000-0002-0276-6056
Truc DoDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ 08544, USA.ORCID 0000-0001-7212-0296
A James LinkDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ 08544, USA.ORCID 0000-0001-5066-9691

Funding

Lasso Peptide DiscoveryR01GM107036 · NIGMS · PRINCETON UNIVERSITY · PI LINK, AARON JAMES · 2014 to 2022
$2.9M
NIGMS NIH HHS R01 GM107036
6 · The paper itself

Abstract

Natural products remain a critical source of medicines and drug leads. One of the most rapidly growing superclasses of natural products is RiPPs: ribosomally synthesized and posttranslationally modified peptides. RiPPs have rich and diverse bioactivities. This review highlights examples of the molecular mechanisms of action that underly those bioactivities. Particular emphasis is placed on RiPP/target interactions for which there is structural information. This detailed mechanism of action work is critical toward the development of RiPPs as therapeutics and can also be used to prioritize hits in RiPP genome mining studies.

Indexed as

Biological ProductsHumansPeptidesProtein BiosynthesisProtein Processing, Post-TranslationalRibosomesBiological ProductsPeptidesMechanism of actionNatural productsRiPPs

Identifiers

PMID33928382
PMCPMC8183687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.